Harvard Pilgrim Health Care | TUFTS Health Plan

Point32Health companies

Payment Policy:

Laboratory: Testing of Homocysteine Metabolism-Related Conditions

Effective date: Nov. 1, 2025

Applies to:

Commercial Products

☒ Harvard Pilgrim Health Care Commercial products
☐ Tufts Health Plan Commercial products

Public Plans Products

☐ Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product)
☐ Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans
☐ Tufts Health RITogether – A Rhode Island Medicaid Plan
☐ Tufts Health One Care – A dual-eligible product

Senior Products

☐ Tufts Health Plan Senior Care Options (SCO) (a dual-eligible product)
☐ Tufts Medicare Preferred HMO/PPO (Medicare Advantage products)

Policy

Homocystinuria is a metabolic condition in which the body is unable to properly process certain amino acids, resulting in an abnormal accumulation of homocysteine and its metabolites in the blood and urine. Homocystinuria is primarily due to genetic causes; however, homocystinuria can also be due to non-genetic causes, including severe deficiency of vitamin B12, also known as cobalamin.

Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

1. Newborn screening for homocysteine-related conditions **MEETS COVERAGE CRITERIA** in any of the following situations:
   a. Screening for classic homocystinuria due to CBS deficiency by performing quantitative plasma amino acids analysis and/or plasma or urine total homocysteine analysis.
   b. Screening for homocystinuria in dried blood spots.
   c. Screening for hypermethioninemia in dried blood spots.
2. When the initial screening test result exceeds the cut-off level of methionine, a repeat dried blood specimen submitted to the newborn screening program, or a quantitative plasma amino acid analysis and analysis of plasma total homocysteine **MEETS COVERAGE CRITERIA**.
3. For individuals over 18 years of age with homocystinuria suspected to be caused by CBS deficiency and for monitoring therapy in those with confirmed CBS deficiency, total homocysteine testing in plasma **MEETS COVERAGE CRITERIA**.
4. Plasma free homocysteine testing **DOES NOT MEET COVERAGE CRITERIA**.

Applicable CPT/HCPCS Procedure Codes

Procedure codes appearing in policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Coding

Code	Description
82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen
82139	Amino acids, 6 or more amino acids, quantitative, each specimen
82615	Cystine and homocysteine, urine, qualitative

Code	Description
83090	Homocysteine
83921	Organic acid, single, quantitative

Evidence-based Scientific References

1. NIH. Homocystinuria due to CBS deficiency. https://rarediseases.info.nih.gov/diseases/6667/homocystinuria-due-to-cbs-deficiency
2. Mudd SH, Finkelstein JD, Refsum H, et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arteriosclerosis, thrombosis, and vascular biology. Jul 2000;20(7):1704-6.
3. Zhu H, Blake S, Chan KT, Pearson RB, Kang J. Cystathionine beta-Synthase in Physiology and Cancer. BioMed research international. 2018;2018:3205125. doi:10.1155/2018/3205125
4. Mazaheri, Mostofizadeh, Hashemipour. Homocystinuria with Stroke and Positive Familial History. Adv Biomed Res. 2017;
5. Li, Barshop, Feigenbaum, Khanna. Brain Magnetic Resonance Imaging Findings in Poorly Controlled Homocystinuria. J Radiol Case Rep. 2018;
6. Ismayilova N, MacKinnon AD, Mundy H, Fallon P. Reversible Cerebral White Matter Abnormalities in Homocystinuria. JIMD Rep. 2019;44:115-119. doi:10.1007/8904_2018_135
7. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. American journal of human genetics. Jan 1985;37(1):1-31.
8. Gaustadnes M, Ingerslev J, Rütiger N. Prevalence of Congenital Homocystinuria in Denmark. New England Journal of Medicine. 1999/05/13 1999;340(19):1513-1513. doi:10.1056/NEJM199905133401915
9. Janosík M, Sokolová J, Janosíková B, Krijt J, Klatovská V, Kozich V. Birth prevalence of homocystinuria in Central Europe: frequency and pathogenicity of mutation c.1105C>T (p.R369C) in the cystathionine beta-synthase gene. The Journal of pediatrics. 2009;154(3):431-437. doi:10.1016/j.jpeds.2008.09.015
10. Al-Sadeq DW, Nasrallah GK. The Spectrum of Mutations of Homocystinuria in the MENA Region. Genes (Basel). Mar 20 2020;11(3)doi:10.3390/genes11030330
11. Rosenson RS, Smith CC, Bauer KA. Overview of homocysteine. Updated January 24, 2025. https://www.uptodate.com/contents/overview-of-homocysteine
12. Abbott MH, Folstein SE, Abbey H, Pyeritz RE. Psychiatric manifestations of homocystinuria due to cystathionine beta-synthase deficiency: prevalence, natural history, and relationship to neurologic impairment and vitamin B6-responsiveness. American journal of medical genetics. Apr 1987;26(4):959-69. doi:10.1002/ajmg.1320260427
13. Rose NC, Dolan SM. Newborn screening and the obstetrician. Obstetrics and gynecology. 2012;120(4):908-917. doi:10.1097/AOG.0b013e31826b2f03
14. Sacharow SJ, Picker JD, Levy HL. Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews((R)). University of Washington, Seattle; 2004.
15. Froese DS, Kopec J, Fitzpatrick F, et al. Structural Insights into the MMACHC-MMADHC Protein Complex Involved in Vitamin B12 Trafficking. The Journal of biological chemistry. Dec 4 2015;290(49):29167-77. doi:10.1074/jbc.M115.683268
16. Wang W, Jiao XH, Wang XP, Sun XY, Dong C. MTR, MTRR, and MTHFR Gene Polymorphisms and Susceptibility to Nonsyndromic Cleft Lip With or Without Cleft Palate. Genetic testing and molecular biomarkers. Jun 2016;20(6):297-303. doi:10.1089/gtmb.2015.0186
17. Collison FT, Xie YA, Gambin T, et al. Whole Exome Sequencing Identifies an Adult-Onset Case of Methylmalonic Aciduria and Homocystinuria Type C (cblC) with Non-Syndromic Bull's Eye Maculopathy. Ophthalmic Genet. 2015;36(3):270-5. doi:10.3109/13816810.2015.1010736
18. Nelson BC, Pfeiffer CM, Sniegoski LT, Satterfield MB. Development and evaluation of an isotope dilution LC/MS method for the determination of total homocysteine in human plasma. Analytical chemistry. Feb 15 2003;75(4):775-84.
19. Belkhiria MN, Ducros V, Harzallah K, et al. [Evaluation of plasmatic homocysteine determination by gas chromatography-mass spectrometry]. Annales de biologie clinique. Jul-Aug 2007;65(4):393-8. Evaluation d'un transfert de methode : dosage de l'homocysteine plasmatique par chromatographie en phase gazeuse couplee a la spectrometrie de masse.
20. Nexo E, Engbaek F, Ueland PM, et al. Evaluation of Novel Assays in Clinical Chemistry: Quantification of Plasma Total Homocysteine. Clinical Chemistry. 2000;46(8):1150.
21. Concepción-Alvarez A, Camayd-Viera I, Nuevas-Paz L. Validation of an HPLC method for total homocysteine quantification in plasma. Revista del Laboratorio Clinico. 2016;9(2):40-47. doi:10.1016/j.labcli.2016.02.003
22. de Sain-van der Velden MGM, van der Ham M, Jans JJ, et al. Suitability of methylmalonic acid and total homocysteine analysis in dried bloodspots. Anal Chim Acta. Jan 1 2015;853:435-441. doi:10.1016/j.aca.2014.10.043
23. Long S, Goldblatt J. MTHFR genetic testing: Controversy and clinical implications. Australian Family Physician. 4/01 2016;45:237-240.
24. Gonzales MC, Yu P, Shiao SPK. MTHFR Gene Polymorphism-Mutations and Air Pollution as Risk Factors for Breast Cancer: A Metaprediction Study. Nursing research. 2017;66(2):152-163. doi:10.1097/NNR.0000000000000206

25. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature genetics. May 1995;10(1):111-3. doi:10.1038/ng0595-111
26. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Molecular genetics and metabolism. Jul 1998;64(3):169-72. doi:10.1006/mgme.1998.2714
27. Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood. Apr 1 2003;101(7):2483-8. doi:10.1182/blood.V101.7.2483
28. Harmon DL, Shields DC, Woodside JV, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genetic epidemiology. Nov 1999;17(4):298-309. doi:10.1002/(sici)1098-2272(199911)17:4<298::Aid-gepi5>3.0.Co;2-v
29. Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis. Aug 2001;157(2):451-6.
30. Gales A, Masingue M, Millecamps S, et al. Adolescence/adult onset MTHFR deficiency may manifest as isolated and treatable distinct neuro-psychiatric syndromes. Orphanet J Rare Dis. Feb 1 2018;13(1):29. doi:10.1186/s13023-018-0767-9
31. Okun JG, Gan-Schreier H, Ben-Omran T, et al. Newborn Screening for Vitamin B6 Non-responsive Classical Homocystinuria: System
32. Guo Q-n, Wang L, Liu Z-y, et al. Different effects of maternal homocysteine concentration, MTHFR and MTRR genetic polymorphisms on the occurrence of fetal aneuploidy. Reproductive BioMedicine Online. 2022/12/01/ 2022;45(6):1207-1215. doi:10.1016/j.rbmo.2022.06.024
33. HHS. Recommended Uniform Screening Panel. Updated July, 2024. https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html
34. ACMG. Newborn Screening ACT Sheet [Increased Methionine] Homocystinuria (CBS Deficiency) Updated December, 2021. https://www.acmg.net/PDFLibrary/Methionine.pdf
35. ACMG. Methionine Elevated or Decreased. American College of Medical Genetics and Genomics. Updated December, 2021. http://www.acmg.net/PDFLibrary/Methionine-Algorithm.pdf
36. Huemer M, Kožich V, Rinaldo P, et al. Newborn screening for homocystinurias and methylation disorders: systematic review and proposed guidelines. Journal of inherited metabolic disease. 2015;38(6):1007-1019. doi:10.1007/s10545-015-9830-z
37. Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40(1):21-48. doi:10.1007/s10545-016-9991-4
38. Morris AAM, Kožich V, Santra S, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. journal article. January 01 2017;40(1):49-74. doi:10.1007/s10545-016-9979-0
39. FDA. Invader MTHFR 677 510(k) Summary. 2021. Updated May 13, 2011. https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100987.pdf
40. FDA. Invader MTHFR 1298 510(k) Summary. 2021. Updated April 25, 2011. https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100496.pdf
41. FDA. eSensor Thrombophila Risk Test on XT-8 System. Updated March 24, 2010. https://www.accessdata.fda.gov/cdrh_docs/pdf9/K093974.pdf
42. FDA. Nanosphere 510(k) Summary. Updated October 11, 2007. https://www.accessdata.fda.gov/cdrh_docs/pdf7/K070597.pdf

Publication History

03/01/2026: Annual review; removed 84207 from coding grid; administrative edits
09/01/2025: Policy created to support coverage guidelines, effective for dates of service beginning Nov. 1, 2025

Background and Disclaimer Information

This policy applies to the products of Harvard Pilgrim Health Care and Tufts Health Plan and their affiliates, as identified in the check boxes on the first page for services performed by contracted providers.

Payment is based on member benefits and eligibility on the date of service, medical necessity review, where applicable, and the provider's network participation agreement with the Plan. As every claim is unique, this policy is neither a guarantee of payment, nor a final indication of how specific claim(s) will be adjudicated. Claims payment is subject to member eligibility and benefits on the date of service, coordination of benefits, referral/authorization, and utilization management requirements (when applicable), adherence to Plan policies and procedures, and claims editing logic. An authorization is not a guarantee of payment.

Point32Health reserves the right to amend a payment policy at its discretion. CPT and HCPCS codes are updated as applicable; please adhere to the most recent CPT and HCPCS coding guidelines.

We reserve the right to conduct audits on any provider and/or facility to ensure accuracy and compliance with the guidelines

stated in this payment policy. If such an audit determines that a provider/facility did not comply with this payment policy, Harvard Pilgrim Health Care and Tufts Health Plan will expect the provider/facility to refund all payments related to noncompliance.